These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19229667)

  • 1. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
    Dutcher JP; de Souza P; McDermott D; Figlin RA; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Hudes G
    Med Oncol; 2009; 26(2):202-9. PubMed ID: 19229667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
    Figlin RA; de Souza P; McDermott D; Dutcher JP; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Boni J; Hudes G
    Cancer; 2009 Aug; 115(16):3651-60. PubMed ID: 19526589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
    Kwitkowski VE; Prowell TM; Ibrahim A; Farrell AT; Justice R; Mitchell SS; Sridhara R; Pazdur R
    Oncologist; 2010; 15(4):428-35. PubMed ID: 20332142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
    Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
    Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
    J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
    Maroto JP; Hudes G; Dutcher JP; Logan TF; White CS; Krygowski M; Cincotta M; Shapiro M; Duran I; Berkenblit A
    J Clin Oncol; 2011 May; 29(13):1750-6. PubMed ID: 21444868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
    Plimack ER; Tan T; Wong YN; von Mehren MM; Malizzia L; Roethke SK; Litwin S; Li T; Hudes GR; Haas NB
    Oncologist; 2014 Apr; 19(4):354-5. PubMed ID: 24674872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 14. Temsirolimus: in advanced renal cell carcinoma.
    Simpson D; Curran MP
    Drugs; 2008; 68(5):631-8. PubMed ID: 18370442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.
    Bellmunt J; Szczylik C; Feingold J; Strahs A; Berkenblit A
    Ann Oncol; 2008 Aug; 19(8):1387-1392. PubMed ID: 18385198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
    Paule B; Brion N
    Anticancer Res; 2011 Jan; 31(1):331-3. PubMed ID: 21273619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.
    Alemao E; Rajagopalan S; Yang S; Curiel RE; Purvis J; Al MJ
    J Med Econ; 2011; 14(2):245-52. PubMed ID: 21417551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases.
    Areses MC; Herranz UA; Ferrán BB; Mateos LL; González JG; López RL
    Med Oncol; 2012 Jun; 29(2):795-8. PubMed ID: 21560067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.